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Summary.-Rabbits were injected with VX2 cancer cells into the left thigh or tibia,
and given indomethacin 1-16 mg/kg daily starting on the day before tumour implant-
ation or7, 14 or 21 days after implantation. Indomethacin at 2 mg/kg and abovefrom
before tumour implantation reduced osteoclast proliferation and the amount of
prostaglandin-like material extracted from homogenates of excised tumours, but
the inhibition of bone destruction in vivo was significant only with indomethacin at
4 mg/kg and above. Indomethacin at 8 mg/kg reduced osteoclast proliferation and
bone destruction, but the effect was statistically significant only when given within
7 days of inoculation with the tumour.
The place of indomethacin and other inhibitors of prostaglandin synthesis has not
yet been established in the management of patients with skeletal metastases. Drug
administration might need to be started at the time of diagnosis and removal of the
primary tumour, rather than when skeletal metastases are evident.
THERE IS much evidence that the de-
velopment of skeletal metastases is asso-
ciated with the ability of cancer cells to
form prostaglandins (Powles et al., 1973;
Bennett et at., 1975, 1977; Voelkel et al.,
1975; Galasko & Bennett, 1976). Further-
more, prostaglandin-synthesis inhibitors
of the aspirin type inhibit the following:
hypercalcaemia and osteolysis in rats with
the Walker tumour (Powles et al., 1973);
hypercalcaemia in patients with various
non-haematological tumours (Seyberth et
al., 1975); osteolysis and osteoclast pro-
liferation in rabbits bearing the VX2
carcinoma (Galasko & Bennett, 1976).
However, in these experiments treatment
with prostaglandin-synthesis inhibitors
was started at the time oftumour inocula-
tion, unlike the timing of therapy that
would be feasible in man. This paper ex-
amines the importance of administering
indomethacin at appropriate times and
dosages to obtain maximum effects on
tumour prostaglandin formation, osteo-
clast proliferation and osteolysis.
MATERIALS AND AIETHODS
The VX2 carcinoma wias chosen since pre-
vious studies (e.g. Galasko & Bennett, 1976)
showr it to be a good model of skeletal de-
struction bytumour. Tumour-cell suspensions,
prepared as described previously (Galasko,
1976) were administered to New Zealand
white rabbits of either sex weighing about
3 kg. The rabbits were housed in individual
cages and killed 28 days or, sometimes, up to
35 days later.
There were 4 separate experiments. In the
first, 1 ml tumour cell suspension (2-5 x 106
cells/ml) was injected into the left thigh
muscle of each rabbit. Fifty-eight rabbits
were given indomethacin (8 mg/kg daily) in
their drinking water, starting on the day of
tumour implantation or 1, 7, 14 or 21 days
after implantation (9, 14, 12, 12 and 11
rabbits respectively). The indomethacin was
dissolved in ethanol (5 mg/ml) which wasPROSTAGLANDINS AND BONE DESTRUCTION BY TUMOUR
added to the drinking water of the test
animals. During the first 3 weeks each animal
drank its own supply of water containing the
daily dose, and was given more water alone
if required. However, during the 4th week,
when the animals were becoming ill from
disseminated carcinoma, the fluid consump-
tion occasionally diminished. Fifty-eight
animals served as controls, each being paired
with an experimental animal and receiving
tumour from the same donor. Each pair of
animals was killed simultaneously, and
weighed amounts of tumour were examined
for prostaglandin-like material (Bennett et al.,
1973). Tissue was homogenized in either 50%O
ethanol acidified to pH 3 with formic acid
to indicate "basal" amounts, or in Krebs
solution wihich allowNNs prostaglandin syn-
thesis from endogenous precursors released
during tissue disruption (yielding "total"
prostaglandins, since it includes newly syn-
thesized and "basal" amounts). The prosta-
glandin-like material, characterized in other
studies as mainly PGE2 (Voelkel et al., 1975;
Galasko & Bennett, 1976) w%Aas extracted and
assayed against PGE2 using a rat gastric
fundus strip preparation, as described by
Unger et al. (1971).
In the 2nd experiment, 72 rabbits wiere
subdivided into 6 equal groups. Each rabbit
was injected with 1 ml tumour-cell suspen-
sion into the left thigh muscle. One group
served as controls, and the remainder re-
ceived 1, 2, 4, 8 or 16 mg indomethacin/kg
daily in their drinking w%Nater, starting one day
before the injection of cancer cells. Six
animals (one from each group) received
tumour from the same donor, and were killed
simultaneously. Tumour prostaglandins were
examined as in the first experiment.
In the 3rd experiment, 104 rabbits wvere
each injected with 1 ml tumour-cell suspen-
sion into the left tibia through a drill hole
(Galasko & Bennett, 1976). Thirty animals
served as controls, and the remainder were
given indomethacin in their drinking water as
followis: 1, 2, 4, 8 or 16 mg/kg daily starting
on the day prior to tumour implantation; or
8 mg/kg daily starting the day prior to, or 1,
7, 14 or 21 days after, tumour implantation.
Animals in each group were killed simul-
taneously, and the tibiae decalcified in 500
nitric acid after removal. Longitudinal sec-
tions were cut through the middle ofthe tibia
and its tumour. After staining with haemat-
oxylin and eosin, the sections were examined
using a light microscope ( x 275) with a cross-
hatched graticule. An osteoclast was counted
if it lay under one of the cross-hatches, but
not if it lay between 2 cross-hatches
(Galasko & Bennett, 1976). Six hundred
randomly selected sites along bone edges
were examined in each of2 sections from each
tibia, and the number of osteoclasts per 600
sites was calculated.
The amount ofbone destruction (number of
squares per longitudinal section) was meas-
ured in 2 sections from each tibia, using a
cross-hatched graticule w%ith a grid of 10 x 10
squares (magnification x 20).
In the 4th experiment, 1mm cubes of VX2
tumour growing in the thigh ofindomethacin-
treated animals wAere incubated in modified
Bigger's medium (Harris et al., 1973) at 37°C
in an atmosphere of 5% CO2 in air for 48 h,
and then incubated for a further 48 h with
mouse calvaria. Osteolysis was estimated by
measuring calcium release into the culture
fluid, using absorption spectrometry.
RESULTS
The results, shown in Tables I to IV,
are means + s.e. analysed using Student's
t test for paired or unpaired data as
appropriate.
TABLE I. Indomethacin at 8 mg/kg daily, started at any time relative to tumour trans-
plantation, reduced basal and total amounts of extracted prostaglandin-like material
(,ug PGE2 equivalents/g). Day 0 is day of VX2 tumour implantation
Basal PG
Control Indo. group
2-37 + 0.55 0-21 + 0-14***
2-13 + 0-33 0-70 + 039**
1-80 + 0-52 0.30 + 0-19*
3 50+ 0-96 0-32+ 0-17*
1*66 + 0-48 0-62 + 0.17*
Total PG
Control Indo. group
4-37 + 1-01 0-17+0-06**
3 97 + 0 81 1-37 + 0.58*
4-83 + 1-12 0-60 + 0.37**
4-48 1-48 0.77 + 0-43*
3-02 + 1*16 1.70 + 0-80*
*P<0.05, ** P<0.01, ***P<0.001.
Day
treatment
started
0
1
7
14
21
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TABLE II. Indomethacin at leacst 2 mg/kg
daily started one day before inoculation
with tumour and continued for 28 days,
significantly reduced amounts of extracted
basal and totalprostaglandin-like material
(tg PGE2 equivalents/g)
In(lo-
mnetliacin
(mg/kg)
daily
0
1
2
4
8
16
Basal P'G
2-01 + 0-28
1-42 + 0-39
0-41 + 0-06**
0)46+ 0.15**
0-24 + 0.09***
0.29+0.12***
Total PG
3-21 +0-66
:3-26+ 1-37
0-90 + 0 14*
1.29+0.44*
0 98 + 0(:X8**
1(1 + 0.42*
*P<0.05, **P)<0.0)I ***<J)< ol.
The first experiment indicates that
indomethacin at 8 mg/kg daily reduced
the amounts ofprostaglandin-like material
extracted from tumour homogenates, re-
gardless of the tumour "age" at the start
of drug administration. As the tumour
grew it outstripped its blood supply, so
that after 3 weeks there was a small rim
of fleshy tumour, - 2 mm thick, surround-
ing a large liquefied necrotic centre con-
taining tumour cells that seemed viable
on histological examination. Tumour
necrosis might explain the tendency for a
smaller inhibition of prostaglandin syn-
thesis with indomethacin started when the
tumours were 21 days old, perhaps partly
because of poor drug penetration.
Indomethacin at, 2 mg/kg and more per
day started one day before inoculation
with tumour significantly reduced the
amounts of prostaglandin extracted from
homogenates of tumours removed after 28
days (Table II). (The lack of a significant
effect of I mg/kg on "total" or "basal"
prostaglandin might be due to the dilution
ofindomethacin within the tumour during
homogenization in Krebs solution, tihus
allowing prostaglandiii synthesis.)
Indomethacin in doses of at, least 2 mg/
kg started one day before inoculation with
tumour significantly reduced the amounts
of prostaglandin and osteoclast prolifera-
tion; the inhibition of bone destruction
was statistically significant only with
4 mg/kg and above, probably because of
the small numbers at the lower doses
(Table III). The effects of different doses
of indomethacin on amounts of prosta-
glandin, osteoclast proliferation and bone
destruction tended to followr the same
curve (Fig.).
Indomethacin at 8 lmg/kg significantly
reduced osteoclast proliferation and bone
destruction only when started within 7
days of tumour inoculation (Table IV).
TABLE III. All doses of indomnethacin reduced osteoclast proliferation (cells), but the effect
was greatest with doses of 8 and 16 mg/kg. Indomethacin also reduces bone destruction
(lysis), but the effect was statistically significant only with 4 mg/kg and above. The results
on each horizontal line were obtained with the same initial cell suspension
Ilndometlbacii (laily (mg/kg)
0
C'ells LYSiS
180 369
105 346
177 4:32
180 641
180 335
1 77 805
177 805
Mleanl 168 5133
S.e. 10.5 80:3
J) <
Cells lJvsis Cells Lysis
111 :3:39
4
Cels Lysis
80 281
108 :302 102 345 78
69
156 334 126 142 81
111 140 114 242 72
129
123 258 111 267 85
15 5 60)0 4-9 47-9 9.0
(. 1 0(4 0001 02- (0(0(1 ()(05 (0-(1 001 ((001 ()0(1
Cells =osteoclasts/60() sites.
Lysis=tthe amotunt of bone (lestrluction measuredl as squares in anl eepiece graticule.
P, coImpalrison withi (Oltrols (0 ind(Iomethla(in).
8
:36
21
24
48
81
69
3:3
45
8 6
15:3
415
1:31
107
64:3
:308
81*5
Lysis
227
115
194
343
97
:303
3106
226
365
16
Ce'lls Lysis
931 204
12 78
6 255
51 169
54 3100
:.39 430
43 2391
12 9 49( 1
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TABLE IV.-Indomethacin at 8 mg/kg daily reduced osteoclast proliferation and bone
destruction, but the effects were statisticallysignificantonlywhen indomethacin was started
wivithin 7 days of tumour inoculation. The results on each horizontal line were obtained
with the samte initial cell suspension. Those at 14 and 21 days (a and b respectively)
are combined because of the small numbers of tumours. Wf1hen indomethacin was started
at 7 days there was less bone destruction than when started at 14/21 days(P < 002) but
the tendencyforfewer osteoclasts is not statistically significant (P > 0.2)
Control
C'ells Lysis
19
42 228
:33 120
172 202
156 187
97 :3:35
132 675
222 875
177 8(5
153 887
- I
Cells Lysis
0 0
18 94
63 124
54 87
24 79
24 161
15 298
:33 :306
57 368
Day of starting in(lomethiacin 8 mg/kg
1 7 14a an(l 21b
Cells L,ysis 'Cells Lysis Cells Lysis
18
60
48
90
138
98
36
53
0
124
95
63
174
427
431
78
100
114
96
66
84
164
154
338
428
445
42a; 1681 385a; 5541)
117a; 1531' 618a; 7011'
1(,)a 628a
Mtean 120 476 329 169 68 188 89 316 116 557
S.e. 21 9 107-5 7.0 41 9 13-7 65-5 7 0 64-7 2 1 53-4
p< (-0001 0.01 0(02 0-02 0.05 0-05 1.0 0(5
Osteolysis in 28 + 0)2 20+0(2 1-8+ 0-3a
culture (IP<0)01) (P<0 01)
(mg calcium 1-5 + 0.21)
released) (P< 0-01)
C'ells =osteoclasts/600 sites.
Lysis=tthe amount of bone (lestruction measured as squares in an eyelpiece grati(ule.
-1 is the day before tumourl implantation.
P, comparison with controls.
Tumours from animals treated witli in(domethacin produce(d significantly less osteolysis in culture, regard-
less of wvhen treatment with in(domethiacin was started.
Because the number ofrabbitsinwhom the
indomethacin was started 14 days or 21
days after tumour transplantation are
small they have been combined for statis-
tical analysis. These results were not sig-
niificantly different from controls, and
the amount of bone destruction was
greater than in rabbits given indo-
methacin from Day 7 onwards (Table IV).
All tumours removed from animals
treated with indomethacin produced sig-
nificantly less osteolysis than controls in
culture with mouse calvarium (Table IV).
This occurred irrespective of the timing of
drug administration, even though indo-
methacin was not added to the culture
medium, and despite prior tumour culture
without indomethacin for 48 h. Thus some
cyclo-oxygenase may have been inhibited
by residual indomethacin, or some of the
enzyme may have been irreversibly in-
hibited (Lands et al., 1973).
D)ISCUSSION
Our experiments confirm and extend
previous results obtained by ourselves and
others. Administration ofindomethacin to
rabbits can reduce the formation of
prostaglandin-like material by VX2
tumours, reduce osteoclast proliferation,
and inhibit bone destruction (Voelkel et
al., 1975: Galasko & Bennett, 1976). The
timing of drug administration is import-
ant, but has not previously been ex-
amined with regard to the growth of
tumours in bone. Galasko (1976) found
2 main phases of bone destruction by
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3- 600
.20
4200°| X + -P total
+ + * *~~ osteoclasts
010 10~ ~ ~
PG basal
2" 400 O i 2 4 8 16mg/kg indo
(7) (3) (4) (6) (7) (6) (n)
FIG.-Curves for tlle mean effects of different
dose3s of indometliacin on amounts of ex-
tracted prostaglandin-like material, ntim-
bers3 of osteoclast,s and bone destruct,ion
(bone) are of similar sbape. Vertical axes:
PG (yug PGE2 equivalents/g); bone destrtic-
tion (number ofsquares); osteoclasts (num-
ber/600 sites).
skeletal metastases. The first phase is
mediated by osteoclasts which are stimu-
lated by various prostaglandins; in the
second phase the osteoclasts disappear,
despite continued bone destruction. In
our experiments indomethacin reduced
osteoclast proliferation and bone destruc-
tion significantly when it was given
within one week of inoculation with
tumour; there was no significant effect on
bone destruction with later administra-
tion.
The place of indomethacin and other
non-steroidal inhibitors of prostaglandin
synthesis has not yet been established in
the management of patients with skeletal
metastases. If these drugs are to be of
value, administration may have to be at
the time of diagnosis and removal of the
primary tumour, rather than withheld
until skeletal metastases are evident.
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